

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

**214410Orig1s000
210854Orig1s004,s010**

OFFICER/EMPLOYEE LIST

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: November 19, 2020

TO: Administrative file for NDA 214410/Original 1

FROM: Christine Kim, PharmD, Regulatory Project Manager
Antivirals Group, Division of Regulatory Operations for Infectious Diseases
Office of Regulatory Operations

SUBJECT: Officer/Employee List for NDA 214410/Original 1

APPLICATION/DRUG: NDA 214410/Original 1, XOFLUZA (baloxavir marboxil)
Oral suspension

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Al Hakim, Ali
Baylor, Melisse
Birnkrant, Debra
Bunner, Anne
Diggs, Deacqunita
Earp, Justin
Englund, Erika
Fuller, Barbara
Ghantous, Hanan
Ince, William
John, Mathew
Kim, Christine
Kolejian, Sevan
Liu, Jinzhong
Mayrosh, Ruth
Min, Stacey
Murray, Jeffrey
Oliver, Thomas
O'Rear, Julian
Ossareh, Nima
Reynolds, Kellie
Sampson, Mario
Schu, Daniel

Singer, Mary
Smith, Fraser
Vaughan, Valerie
Wang, Hailin

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

CHRISTINE KIM
11/19/2020 03:16:43 PM